BATON ROUGE – Mary Bird Perkins Cancer Center has introduced the enrollment of its first sufferers in part 1 scientific trials.
The facility’s inaugural part 1 trial is designed to reinforce look after sufferers recognized with diffuse massive B cell lymphoma, a kind of non-Hodgkin lymphoma that’s frequent and extremely aggressive. From 2017-2020, there have been 357 sufferers recognized with the illness in Louisiana.
Phase 1 scientific trials are the earliest stage of testing for brand spanking new therapies in people, typically involving a small variety of individuals. Later part scientific trials develop to bigger teams of sufferers.
“Phase 1 trials require a level of expertise and resources only available at the highest-performing cancer centers, offer patients additional options for treatment, and help raise the standard of cancer care in a region when they are offered,” mentioned a Mary Bird Perkins spokesperson.
Victor Lin, Mary Bird Perkins’ medical director for scientific analysis, is answerable for the growth of trial choices.
“Phase 1 trials are new and exciting, but they require meticulous attention to detail and vigilance to appropriately safeguard our patients,” mentioned Lin. “With support and generosity from the local community, Mary Bird Perkins has made a substantial investment in the infrastructure required to undertake these complex protocols. We are committed to bringing more access to high-quality clinical trials to the Gulf South, with a particular emphasis on ensuring that the patients we enroll will more accurately reflect our diverse community. The data we gather contributes to global research efforts, ultimately benefiting individuals worldwide.”
“Mary Bird Perkins was founded by residents of Louisiana to provide access to leading cancer therapies and technologies,” mentioned Jonas Fontenot, Mary Bird Perkins president and chief govt officer. “Our team continues to set the standard for high-quality cancer care and research throughout the region. The phase 1 clinical trials program being developed by Dr. Lin and his team marks the latest milestone in our commitment to improve survivorship and lessen the burden of cancer.”
